Clinical Trial Update: Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 study evaluating pembrolizumab (MK-3475) alone or with copanlisib in relapsed or refractory NK/T-cell non-Hodgkin lymphoma; the trial status is term…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• Copanlisib (copanlisib)
• MK-3475 (pembrolizumab)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Lymphoma, T-Cell, Peripheral | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-07-08